Special Issue "Nanotechnology and Cancer Therapeutics"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 November 2010)

Special Issue Editor

Guest Editor
Dr. Shaker A. Mousa
Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, New York 12144, USA
E-Mail: shaker.mousa@acphs.edu
Phone: +1 518 694 7397
Fax: +1 518-694 7567
Interests: Drug discovery and drug development utilizing key enabling technologies including nanotechnology; biotechnology, stem cell, and novel pharmacotherapy; cell adhesion molecules and extracellular matrix; treatment and prevention of ischemic and coronary artery diseases; angiogenesis modulation; vascular and tissue remodeling; novel anti-platelet, anti-thrombotic and early detection and treatment of diseases with unmet medical need ranging from oncology, ophthalmology, cardiovascular, and vascular disorders

Special Issue Information

Dear Colleagues,

I would like to take this opportunity in inviting review articles having key innovations that would help accelerate progress in the field of Nanotechnology in early cancer detection and treatment. It is becoming clear to all of us that the application of nanotechnology and biotechnology utilizing nanoparticles for combined targeting and delivery of diagnostic and therapeutic agents has tremendous potential for early detection and treatment of various disorders. Nanoparticles may be constructed from a wide range of organic and inorganic materials such as emulsions, micelles, liposomes, dendrimers, quantum dots, and other polymeric materials. These materials are being used to encapsulate or covalently bind to the surface of the nanoparticles site directed moiety (s). Several multifunctional nanoparticles are being evaluated in early detection and therapeutics.

The next generation of nanoparticles-based research is directed at the consolidation of functions into strategically engineered multifunctional devices, which may ultimately facilitate the realization of individual therapy. These nanoparticles may be capable of (a) improving delivery of hydrophobic compounds (water insoluble); (b) improving stability of unstable peptides or easily inactivated compounds such as polyphenols and others; (c) identifying malignant cells via molecular detection; (c) visualizing their location in the body by providing enhanced contrast in medical imaging techniques; (d) targeting and killing diseased cells with minimal side effects through selective cell or tissue targeting; (e) polyvalent antidote for reversal of intoxication or toxins; and (f) delivering multiple drug targets for combination therapy.

One of the best known examples for reformulated, nanoparticles-based drug delivery is Doxil. Doxil, approved in the U.S. in 1995, is the poly (ethylene glycol)-coated, liposome-encapsulated form of doxorubicin in cancer chemotherapy. A more recent commercial product Abraxane, consists of an albumin-based reformulation of paclitaxel, which was approved in the U.S. in 2005. Other examples are in preclinical and early clinical investigations.

Dr. Shaker A. Mousa
Guest Editor

Keywords

  • early detection using in vivo imaging modalities
  • biosensor
  • site directed delivery of chemotherapy into different tumor types using specific directed targets metal nanoparticles such as gold nanoparticles in the detection and treatment of breast cancer, and other types of cancer
  • use of nanotechnology with nutraceuticals for chemoprevention

Published Papers (10 papers)

Cancers 2012, 4(4), 1067-1105; doi:10.3390/cancers4041067
Received: 13 August 2012; in revised form: 20 September 2012 / Accepted: 15 October 2012 / Published: 22 October 2012
Show/Hide Abstract | Download PDF Full-text (2057 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(3), 3279-3330; doi:10.3390/cancers3033279
Received: 16 June 2011; in revised form: 7 July 2011 / Accepted: 8 August 2011 / Published: 12 August 2011
Show/Hide Abstract | Download PDF Full-text (889 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 1081-1110; doi:10.3390/cancers3011081
Received: 17 December 2010; in revised form: 19 January 2011 / Accepted: 21 January 2011 / Published: 4 March 2011
Show/Hide Abstract | Download PDF Full-text (1890 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 802-840; doi:10.3390/cancers3010802
Received: 19 January 2011; in revised form: 12 February 2011 / Accepted: 17 February 2011 / Published: 23 February 2011
Show/Hide Abstract | Download PDF Full-text (1984 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 428-445; doi:10.3390/cancers3010428
Received: 14 December 2010; in revised form: 4 January 2011 / Accepted: 12 January 2011 / Published: 21 January 2011
Show/Hide Abstract | Download PDF Full-text (291 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 227-240; doi:10.3390/cancers3010227
Received: 7 December 2010; in revised form: 26 December 2010 / Accepted: 4 January 2011 / Published: 6 January 2011
Show/Hide Abstract | Download PDF Full-text (539 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 61-78; doi:10.3390/cancers3010061
Received: 11 November 2010; in revised form: 20 December 2010 / Accepted: 27 December 2010 / Published: 28 December 2010
Show/Hide Abstract | Download PDF Full-text (1187 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 17-42; doi:10.3390/cancers3010017
Received: 12 November 2010; in revised form: 10 December 2010 / Accepted: 22 December 2010 / Published: 23 December 2010
Show/Hide Abstract | Download PDF Full-text (692 KB) | View HTML Full-text | Download XML Full-text

Cancers 2010, 2(4), 1911-1928; doi:10.3390/cancers2041911
Received: 29 October 2010; in revised form: 10 November 2010 / Accepted: 11 November 2010 / Published: 18 November 2010
Show/Hide Abstract | Download PDF Full-text (815 KB) | Download XML Full-text

Cancers 2010, 2(4), 1884-1894; doi:10.3390/cancers2041884
Received: 28 October 2010; in revised form: 2 November 2010 / Accepted: 9 November 2010 / Published: 17 November 2010
Show/Hide Abstract | Download PDF Full-text (228 KB) | Download XML Full-text

Last update: 25 February 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert